C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, Mcmurray JJV, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA (2016)

Publication Type: Journal article

Publication year: 2016

Journal

American Journal of Kidney Diseases Elsevier

Book Volume: 68

Pages Range: 873-881

Journal Issue: 6

DOI: 10.1053/j.ajkd.2016.07.022

Abstract

To better understand a potential association of elevated C-reactive protein (CRP) level with progression of chronic kidney disease (CKD), we examined the relationship of CRP level with the development of end-stage renal disease (ESRD) in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).Post hoc analysis of a randomized controlled trial.4,038 patients with type 2 diabetes, CKD, and anemia in TREAT.Baseline serum CRP concentrations.The primary outcome was development of ESRD; secondary outcomes included doubling of serum creatinine level, a composite of ESRD/serum creatinine doubling, and a composite of death or ESRD.We fit unadjusted and adjusted Cox regression models to test the association of baseline CRP level with time to the development of the outcomes of interest.Mean age of participants was 67 years, 43% were men, and 64% were white. Approximately half (48%) the patients had CRP levels > 3.0mg/L; 668 patients developed ESRD, and 1,270 developed the composite outcome of death or ESRD. Compared with patients with baseline CRP levels <= 3.0mg/L, those with moderately/markedly elevated CRP levels (>=6.9mg/L; 24% of patients) had a higher adjusted risk for ESRD (HR, 1.32; 95% CI, 1.07-1.63) and the composite outcome of death or ESRD (HR, 1.41; 95% CI, 1.21-1.64). Although nonsignificant, similar trends were noted in competing-risk models.Results may not be generalizable to nondiabetic CKD or diabetic CKD in the absence of anemia.Elevated baseline CRP levels are common in type 2 diabetic patients with anemia and CKD and are associated with the future development of ESRD and the composite of death or ESRD.

Authors with CRIS profile

Kai-Uwe Eckardt Department of Medicine 4 – Nephrology and Hypertension

Involved external institutions

Harvard University US United States (USA) (US) University of São Paulo / Universidade de São Paulo (USP) BR Brazil (BR) Mario Negri Institute for Pharmacological Research (IRCCS) / Istituto di Ricerche Farmacologiche Mario Negri IT Italy (IT) University of Texas Southwestern Medical Center (UT Southwestern) US United States (USA) (US) Memorial University of Newfoundland (MUN) CA Canada (CA) University of Glasgow GB United Kingdom (GB) Tufts University US United States (USA) (US) Amgen Inc. US United States (USA) (US) Brigham and Women's Hospital (BWH) US United States (USA) (US)

How to cite

APA:

Mc Causland, F.R., Claggett, B., Burdmann, E.A., Eckardt, K.-U., Kewalramani, R., Levey, A.S.,... Pfeffer, M.A. (2016). C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 68(6), 873-881. https://doi.org/10.1053/j.ajkd.2016.07.022

MLA:

Mc Causland, Finnian R., et al. "C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)." American Journal of Kidney Diseases 68.6 (2016): 873-881.

BibTeX: Download